Design and modifications of allergens for improving specific immunotherapy

Inflammation and Allergy - Drug Targets

Volumn 7, Issue 4, 2008, Pages 270-278

  Velickovic, Tanya Cirkovic ^a   Jankov, Ratko M ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Allergen; Allergoid; Hypoallergen; Immunotherapy; Modification

Indexed keywords

ALLERGEN; ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; GRASS POLLEN VACCINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G4; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; POLLEN ANTIGEN; DNA;

AIRWAY EOSINOPHILIA; ALLERGIC DISEASE; ALLERGY; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DNA SEQUENCE; DNA SHUFFLING; DOWN REGULATION; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; GENE MUTATION; GENE TARGETING; GRASS POLLEN; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; NONHUMAN; POINT MUTATION; RESPIRATORY TRACT DISEASE; REVIEW; SITE DIRECTED MUTAGENESIS; VACCINATION; ANIMAL; CHEMISTRY; GENETICS; HYPERSENSITIVITY; PROTEIN ENGINEERING;

ADJUVANTS, IMMUNOLOGIC; ALLERGENS; ANIMALS; DNA; DRUG DESIGN; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; PROTEIN ENGINEERING;

EID: 58249089399     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152808786848432     Document Type: Review

References (113)

1. Larche, M.; Akdis, C.A.; Valenta, R. Immunological mechanisms of allergen-specific immunotherapy. Nat. Rev. Immunol., 2006, 6, 761.
2. Passalacqua, G.; Durham, S. R. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J. Allerg. Clin. Immunol., 2007, 119, 881.
3. van Neerven, R.J.; Wikborg, T.; Lund, G.; Jacobsen, B.; Brinch-Nielsen, A.; Arnved, J.; Ipsen, H. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J. Immunol., 1999, 163, 2944.
4. Radulovic, S.; Jacobson, M.R.; Durham, S.R.; Nouri-Aria, K.T. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J. Allergy Clin. Immunol., 2008, 121, 1467, 1472 e1.
5. Pereira-Santos, M.C.; Baptista, A.P.; Melo, A.; Alves, R.R.; Soares, R.S.; Pedro, E.; Pereira-Barbosa, M.; Victorino, R.M.; Sousa, A.E. Expansion of circulating Foxp3+)D25bright CD4+ T cells during specific venom immunotherapy. Clin. Exp. Allergy, 2008, 38, 291.
6. Francis, J.N.; James, L.K.; Paraskevopoulos, G.; Wong, C.; Calderon, M.A.; Durham, S.R.; Till, S.J. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J. Allergy Clin. Immunol., 2008, 121, 1120 e2.
7. Mamessier, E.; Birnbaum, J.; Dupuy, P.; Vervloet, D.; Magnan, A. Ultra-rush venom immunotherapy induces differential T cell activation and regulatory patterns according to the severity of allergy. Clin. Exp. Allergy, 2006, 36, 704.
8. Francis, J.N.; Till, S.J.; Durham, S.R. Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J. Allergy Clin. Immunol., 2003, 111, 1255.
9. Nouri-Aria, K.T.; Wachholz, P.A.; Francis, J.N.; Jacobson, M.R.; Walker, S.M.; Wilcock, L.K.; Staple, S.Q.; Aalberse, R.C.; Till, S.J.; Durham, S.R. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J. Immunol., 2004, 172, 3252.
10. Winther, L.; Arnved, J.; Malling, H.J.; Nolte, H.; Mosbech, H. Side-effects of allergen-specific immunotherapy: a prospective multi-centre study. Clin. Exp. Allergy, 2006, 36, 254.
11. Maasch, H.J.; Marsh, D.G. Standardized extracts modified allergens-allergoids. Clin. Rev. Allergy, 1987, 5, 89.
12. Puttonen, E.; Maasch, H.J.; Pilstrom, L. Studies of allergen and allergoid preparations from purified timothy (Phleum pratense) pollen extracts. I. Physicochemical characteristics and binding to allergen-specific human IgE. Int. Arch. Allergy Appl. Immunol., 1982, 68, 1.
13. Puttonen, E.; Pilstrom, L.; Wahn, U.; Maasch, H.J. Studies on allergen and allergoid preparations from purified timothy (Phleum pratense) pollen extracts. II. Anaphylaxis studies in rats and histamine release from human leukocytes. Int. Arch. Allergy Appl. Immunol., 1982, 68, 7.
14. Bousquet, J.; Frank, E.; Soussana, M.; Hejjaoui, A.; Maasch, H.J.; Michel, F.B. Double-blind, placebo-controlled immunotherapy with a high-molecular-weight, formalinized allergoid in grass pollen allergy. Int. Arch. Allergy Appl. Immunol., 1987, 82, 550.
15. Meriney, D.K.; Kothari, H.; Chinoy, P.; Grieco, M.H. The clinical and immunologic efficacy of immunotherapy with modified ragweed extract (allergoid) for ragweed hay fever. Ann. Allergy, 1986, 56, 34.
16. Frew, A. J.; Powell, R.J.; Corrigan, C.J.; Durham, S.R. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol., 2006, 117, 319.
17. Pree, I.; Reisinger, J.; Focke, M.; Vrtala, S.; Pauli, G.; van Hage, M.; Cromwell, O.; Gadermaier, E.; Egger, C.; Reider, N.; Horak, F.; Valenta, R.; Niederberger, V. Analysis of epitope-specific immune responses induced by vaccination with structurally folded and unfolded recombinant Bet v 1 allergen derivatives in man. J. Immunol., 2007, 179, 5309.
18. King, T.P.; Jim, S.Y.; Monsalve, R.I.; Kagey-Sobotka, A.; Lichtenstein, L.M.; Spangfort, M.D. Recombinant allergens with reduced allergenicity but retaining immunogenicity of the natural allergens: hybrids of yellow jacket and paper wasp venom allergen antigen 5s. J. Immunol., 2001, 166, 6057.
19. Hufnagl, K.; Winkler, B.; Focke, M.; Valenta, R.; Scheiner, O.; Renz, H.; Wiedermann, U. Intranasal tolerance induction with polypeptides derived from 3 noncross-reactive major aeroallergens prevents allergic polysensitization in mice. J. Allergy Clin. Immunol., 2005, 116, 370.
20. Linhart, B.; Hartl, A.; Jahn-Schmid, B.; Verdino, P.; Keller, W.; Krauth, M.T.; Valent, P.; Horak, F.; Wiedermann, U.; Thalhamer, J.; Ebner, C.; Kraft, D.; Valenta, R. A hybrid molecule resembling the epitope spectrum of grass pollen for allergy vaccination. J. Allergy Clin. Immunol., 2005, 115, 1010.
21. Linhart, B.; Jahn-Schmid, B.; Verdino, P.; Keller, W.; Ebner, C.; Kraft, D.; Valenta, R. Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. FASEB J. 2002, 16, 1301.
22. Spiegelberg, H.L.; Horner, A.A.; Takabayashi, K.; Raz, E. Allergen-immunostimulatory oligodeoxynucleotide conjugate: a novel allergoid for immunotherapy. Curr. Opin. Allergy Clin. Immunol., 2002, 2, 547.
23. Tulic, M.K.; Fiset, P.O.; Christodoulopoulos, P.; Vaillancourt, P.; Desrosiers, M.; Lavigne, F.; Eiden, J.; Hamid, Q. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J. Allergy Clin. Immunol., 2004, 113, 235.
24. Tighe, H.; Takabayashi, K.; Schwartz, D.; Van Nest, G.; Tuck, S.; Eiden, J.J.; Kagey-Sobotka, A.; Creticos, P.S.; Lichtenstein, L.M.; Spiegelberg, H.L.; Raz, E. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J. Allergy Clin. Immunol., 2000, 106, (1 Pt 1), 124.
25. Linhart, B.; Valenta, R. Vaccine engineering improved by hybrid technology. Int. Arch. Allergy Immunol., 2004, 134, 324.
26. Creticos, P.S.; Schroeder, J.T.; Hamilton, R.G.; Balcer-Whaley, S.L.; Khattignavong, A.P.; Lindblad, R.; Li, H.; Coffman, R.; Seyfert, V.; Eiden, J.J.; Broide, D. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med., 2006, 355, 1445.
27. Saxon, A.; Kepley, C.; Zhang, K. "Accentuate the negative, eliminate the positive": engineering allergy therapeutics to block allergic reactivity through negative signaling. J. Allergy Clin. Immunol., 2008, 121, 320.
28. Moran, D.M.; Wheeler, A.W.; Overell, B.G.; Woroniecki, S.R. Chemical modification of crude timothy grass pollen extract. III. The effect of glutaraldehyde-induced aggregation on antigenic and immunogenic properties. Int. Arch. Allergy Appl. Immunol., 1977, 54, 315.
29. Salgado, J.; Casadevall, G.; Puignero, V.; Queralt, J. Characterization of allergoids from ovalbumin in vitro and in vivo. Immunobiology, 1996, 196, 375.
30. Kahlert, H.; Grage-Griebenow, E.; Stuwe, H. T.; Cromwell, O.; Fiebig, H.; T cell reactivity with allergoids: influence of the type of APC. J. Immunol., 2000, 165, 1807.
31. Bagnasco, M.; Passalacqua, G.; Villa, G.; Augeri, C.; Flamigni, G.; Borini, E.; Falagiani, P.; Mistrello, G.; Canonica, G.W.; Mariani, G. Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers. Clin. Exp. Allergy, 2001, 31, 54.
32. Mistrello, G.; Roncarolo, D.; Gentili, M.; Zanoni, D.; Falagiani, P. Modified par j I allergen from P judaica pollen and its rate of absorption in rats. Immunol. Lett., 1994, 40, 31.
33. Mistrello, G.; Brenna, O.; Roncarolo, D.; Zanoni, D.; Gentili, M.; Falagiani, P. Monomeric chemically modified allergens: immunologic and physicochemical characterization. Allergy, 1996, 51, 8.
34. Cirkovic, T.D.; Bukilica, M.N.; Gavrovic, M.D.; Vujcic, Z.M.; Petrovic, S.; Jankov, R.M. Physicochemical and immunologic characterization of low-molecular-weight allergoids of Dactylis glomerata pollen proteins. Allergy, 1999, 54, 128.
35. Cirkovic, T.; Gavrovic-Jankulovic, M.; Prisic, S.; Jankov, R.M.; Burazer, L.; Vuckovic, O.; Sporcic, Z.; Paranos, S. The influence of a residual group in low-molecular-weight allergoids of Artemisia vulgaris pollen on their allergenicity, IgE- and IgG-binding properties. Allergy, 2002, 57, 1013.
36. Cirkovic Velickovic, T.D.; Polovic, N.D.; Gavrovic-Jankulovic, M.D.; Burazer, L.; Dergovic-Petrovic, D.; Vuckovic, O.; Drobnjak, O.; Sporcic, Z.; Atanaskovic-Markovic, M.; Jankov, R.M. Artemisia vulgaris pollen allergoids digestibility in the simulated conditions of the gastrointestinal tract. J. Serb. Chem. Soc., 2006, 71, 879.
37. Polovic, N.D.; Cirkovic Velickovic, T.D.; Gavrovic-Jankulovic, M.; Burazer, L.; Dergovic-Petrovic, D.; Vuckovic, O.; Jankov, R.M. IgG binding of mugwort pollen allergens and allergoids exposed to simulated gastrointestinal conditions measured by a self-developed ELISA test. J. Serb. Chem. Soc., 2004, 69, 533.
38. Shakushiro, K.; Yamasaki, Y.; Nishikawa, M.; Takakura, Y. Efficient scavenger receptor-mediated uptake and cross-presentation of negatively charged soluble antigens by dendritic cells. Immunology, 2004, 112, 211.
39. Murphy, J.E.; Tedbury, P.R.; Homer-Vanniasinkam, S.; Walker, J.H.; Ponnambalam, S. Biochemistry and cell biology of mammalian scavenger receptors. Atherosclerosis, 2005, 182, 1.
40. Nicoletti, A.; Caligiuri, G.; Tornberg, I.; Kodama, T.; Stemme, S.; Hansson, G. K. The macrophage scavenger receptor type A directs modified proteins to antigen presentation. Eur. J. Immunol., 1999, 29, 512.
41. Haberland, M.E.; Fogelman, A.M. Scavenger receptor-mediated recognition of maleyl bovine plasma albumin and the demaleylated protein in human monocyte macrophages. Proc. Natl. Acad. Sci. USA, 1985, 82, 2693.
42. Rajagopal, D.; Ganesh, K.A.; Subba Rao, P.V. Modulation of allergen-specific immune responses to the major shrimp allergen, tropomyosin, by specific targeting to scavenger receptors on macrophages. Int. Arch. Allergy Immunol., 2000, 121, 308.
43. Bhatia, S.; Mukhopadhyay, S.; Jarman, E.; Hall, G.; George, A.; Basu, S.K.; Rath, S.; Lamb, J.R.; Bal, V. Scavenger receptor-specific allergen delivery elicits IFN-gamma-dominated immunity and directs established TH2-dominated responses to a nonallergic phenotype. J. Allergy Clin. Immunol., 2002, 109, 321.
44. Bhalla, P.L.; Singh, M.B. Engineered allergens for immunotherapy. Curr. Opin. Allergy Clin. Immunol., 2004, 4, 569.
45. Baumgarten, C.; Kunkel, G.; Rudolph, R. Grass pollen allergoid. Respiration, 1984, 46, 97.
46. Bousquet, J.; Braquemond, P.; Feinberg, J.; Guerin, B.; Maasch, H.; Michel, F. B. Specific IgE response before and after rush immunotherapy with a standardized allergen or allergoid in grass pollen allergy. Ann. Allergy, 1986, 56, 456.
47. Bousquet, J.; Hejjaoui, A.; Skassa-Brociek, W.; Guerin, B.; Maasch, H.J.; Dhivert, H.; Michel, F.B. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. I. Rush immunotherapy with allergoids and standardized orchard grass-pollen extract. J. Allergy Clin. Immunol., 1987, 80, 591.
48. Giordano, T.; Quarta, C.; Bruno, M.E.; Falagiani, P.; Riva, G. Safety, tolerability and efficacy of sublingual allergoid immunotherapy with a 4-day shortened build-up phase. Allerg. Immunol (Paris), 2006, 38, 310.
49. Passalacqua, G.; Albano, M.; Fregonese, L.; Riccio, A.; Pronzato, C.; Mela, G.S.; Canonica, G.W. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet, 1998, 351, 629.
50. Cosmi, L.; Santarlasci, V.; Angeli, R.; Liotta, F.; Maggi, L.; Frosali, F.; Rossi, O.; Falagiani, P.; Riva, G.; Romagnani, S.; Annunziato, F.; Maggi, E. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production. Clin. Exp. Allergy, 2006, 36, 261.
51. Williams, A.; Henzgen, M.; Rajakulasingam, K. Additional benefit of a third year of specific grass pollen allergoid immunotherapy in patients with seasonal allergic rhinitis. Eur. Ann. Allergy Clin. Immunol., 2007, 39, 123.
52. Passalacqua, G.; Pasquali, M.; Ariano, R.; Lombardi, C.; Giardini, A.; Baiardini, I.; Majani, G.; Falagiani, P.; Bruno, M.; Canonica, G. W. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. Allergy, 2006, 61, 849.
53. Palma-Carlos, A.G.; Santos, A.S.; Branco-Ferreira, M.; Pregal, A.L.; Palma-Carlos, M.L.; Bruno, M.E.; Falagiani, P.; Riva, G. Clinical efficacy and safety of preseasonal sublingual immunotherapy with grass pollen carbamylated allergoid in rhinitic patients. A double-blind, placebo-controlled study. Allergol. Immunopathol (Madr), 2006, 34, 194.
54. Keskin, O.; Tuncer, A.; Adalioglu, G.; Sekerel, B.E.; Sackesen, C.; Kalayci, O. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis. Pediatr. Allergy Immunol., 2006, 17, 396.
55. Casanovas, M.; Martin, R.; Jimenez, C.; Caballero, R.; Fernandez-Caldas, E. Safety of immunotherapy with therapeutic vaccines containing depigmented and polymerized allergen extracts. Clin. Exp. Allergy, 2007, 37, 434.
56. Agostinis, F.; Tellarini, L.; Canonica, G.W.; Falagiani, P.; Passalacqua, G. Safety of sublingual immunotherapy with a monomeric allergoid in very young children. Allergy, 2005, 60, 133.
57. Lund, L.; Henmar, H.; Wurtzen, P.A.; Lund, G.; Hjortskov, N.; Larsen, J.N. Comparison of allergenicity and immunogenicity of an intact allergen vaccine and commercially available allergoid products for birch pollen immunotherapy. Clin. Exp. Allergy, 2007, 37, 564.
58. Wurtzen, P.A.; Lund, L.; Lund, G.; Holm, J.; Millner, A.; Henmar, H. Chemical modification of birch allergen extract leads to a reduction in allergenicity as well as immunogenicity. Int. Arch. Allergy Immunol., 2007, 144, 287.
59. Arquint, O.; Helbling, A.; Crameri, R.; Ferreira, F.; Breitenbach, M.; Pichler, W. J. Reduced in vivo allergenicity of Bet v 1d isoform, a natural component of birch pollen. J. Allergy Clin. Immunol., 1999, 104, 1239.
60. Friedl-Hajek, R.; Radauer, C.; O'Riordain, G.; Hoffmann-Sommergruber, K.; Leberl, K.; Scheiner, O.; Breiteneder, H. New Bet v 1 isoforms including a naturally occurring truncated form of the protein derived from Austrian birch pollen. Mol. Immunol., 1999, 36, 639.
61. Schenk, M.F.; Gilissen, L.J.; Esselink, G.D.; Smulders, M.J. Seven different genes encode a diverse mixture of isoforms of Bet v 1, the major birch pollen allergen. BMC Genomics, 2006, 7, 168.
62. Wagner, S.; Radauer, C.; Bublin, M.; Hoffmann-Sommergruber, K.; Kopp, T.; Greisenegger, E.K.; Vogel, L.; Vieths, S.; Scheiner, O.; Breiteneder, H. Naturally occurring hypoallergenic Bet v 1 isoforms fail to induce IgE responses in individuals with birch pollen allergy. J. Allergy Clin. Immunol., 2008, 121, 246.
63. Krebitz, M.; Wiedermann, U.; Essl, D.; Steinkellner, H.; Wagner, B.; Turpen, T. H.; Ebner, C.; Scheiner, O.; Breiteneder, H. Rapid production of the major birch pollen allergen Bet v 1 in Nicotiana benthamiana plants and its immunological in vitro and in vivo characterization. FASEB J., 2000, 14, 1279.
64. Tsai, W.J.; Liu, C.H.; Chen, S.T.; Yang, C.Y. Identification of the antigenic determinants of the American cockroach allergen Per a 1 by error-prone PCR. J. Immunol. Methods, 2003, 276, 163.
65. Gafvelin, G.; Parmley, S.; Neimert-Andersson, T.; Blank, U.; Eriksson, T.L.; van Hage, M.; Punnonen, J. Hypoallergens for allergen-specific immunotherapy by directed molecular evolution of mite group 2 allergens. J. Biol. Chem., 2007, 282, 3778.
66. Wallner, M.; Stocklinger, A.; Thalhamer, T.; Bohle, B.; Vogel, L.; Briza, P.; Breiteneder, H.; Vieths, S.; Hartl, A.; Mari, A.; Ebner, C.; Lackner, P.; Hammerl, P.; Thalhamer, J.; Ferreira, F. Allergy multivaccines created by DNA shuffling of tree pollen allergens. J. Allergy Clin. Immunol., 2007, 120, 374.
67. Westritschnig, K.; Focke, M.; Verdino, P.; Goessler, W.; Keller, W.; Twardosz, A.; Mari, A.; Horak, F.; Wiedermann, U.; Hartl, A.; Thalhamer, J.; Sperr, W. R.; Valent, P.; Valenta, R. Generation of an allergy vaccine by disruption of the three-dimensional structure of the cross-reactive calcium-binding allergen, Phl p 7. J. Immunol., 2004, 172, 5684.
68. Chen, K.W.; Fuchs, G.; Sonneck, K.; Gieras, A.; Swoboda, I.; Douladiris, N.; Linhart, B.; Jankovic, M.; Pavkov, T.; Keller, W.; Papadopoulos, N.G.; Valent, P.; Valenta, R.; Vrtala, S. Reduction of the in vivo allergenicity of Der p 2, the major house-dust mite allergen, by genetic engineering. Mol. Immunol., 2008, 45, 2486.
69. Kahlert, H.; Suck, R.; Weber, B.; Nandy, A.; Wald, M.; Keller, W.; Cromwell, O.; Fiebig, H. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy. Int. Arch. Allergy Immunol., 2008, 145, 193.
70. Saarne, T.; Kaiser, L.; Gronlund, H.; Rasool, O.; Gafvelin, G.; van Hage-Hamsten, M. Rational design of hypoallergens applied to the major cat allergen Fel d 1. Clin. Exp. Allergy, 2005, 35, 657.
71. Drew, A.C.; Eusebius, N.P.; Kenins, L.; de Silva, H.D.; Suphioglu, C.; Rolland, J. M.; O'Hehir R.E. Hypoallergenic variants of the major latex allergen Hev b 6.01 retaining human T lymphocyte reactivity. J. Immunol., 2004, 173, 5872.
72. Swoboda, I.; Bugajska-Schretter, A.; Linhart, B.; Verdino, P.; Keller, W.; Schulmeister, U.; Sperr, W.R.; Valent, P.; Peltre, G.; Quirce, S.; Douladiris, N.; Papadopoulos, N.G.; Valenta, R.; Spitzauer, S. A recombinant hypoallergenic parvalbumin mutant for immunotherapy of IgE-mediated fish allergy. J. Immunol., 2007, 178, 6290.
73. Buhot, C.; Chenal, A.; Sanson, A.; Pouvelle-Moratille, S.; Gelb, M. H.; Menez, A.; Gillet, D.; Maillere, B. Alteration of the tertiary structure of the major bee venom allergen Api m 1 by multiple mutations is concomitant with low IgE reactivity. Protein Sci., 2004, 13, 2970.
74. Orlandi, A.; Grasso, F.; Corinti, S.; Marinaro, M.; Bonura, A.; Boirivant, M.; Colombo, P.; Di Felice, G. The recombinant major allergen of Parietaria judaica and its hypoallergenic variant: in vivo evaluation in a murine model of allergic sensitization. Clin. Exp. Allergy, 2004, 34, 470.
75. Wald, M.; Kahlert, H.; Weber, B.; Jankovic, M.; Keller, W.; Cromwell, O.; Nandy, A.; Fiebig, H. Generation of a low immunoglobulin E-binding mutant of the timothy grass pollen major allergen Phl p 5a. Clin. Exp. Allergy, 2007, 37, 441.
76. Marazuela, E.G.; Rodriguez, R.; Barber, D.; Villalba, M.; Batanero, E. Hypoallergenic mutants of Ole e 1, the major olive pollen allergen, as candidates for allergy vaccines. Clin. Exp. Allergy, 2007, 37, 251.
77. Vrtala, S.; Focke, M.; Kopec, J.; Verdino, P.; Hartl, A.; Sperr, W.R.; Fedorov, A. A.; Ball, T.; Almo, S.; Valent, P.; Thalhamer, J.; Keller, W.; Valenta, R. Genetic engineering of the major timothy grass pollen allergen, Phl p 6, to reduce allergenic activity and preserve immunogenicity. J. Immunol., 2007, 179, 1730.
78. Rupa, P.; Mine, Y. Ablation of ovomucoid-induced allergic response by desensitization with recombinant ovomucoid third domain in a murine model. Clin. Exp. Immunol., 2006, 145, 493.
79. Rupa, P.; Mine, Y. Engineered recombinant ovomucoid third domain can modulate allergenic response in Balb/c mice model. Biochem. Biophys. Res. Commun., 2006, 342, 710.
80. Gilissen, L.J.; Bolhaar, S.T.; Matos, C.I.; Rouwendal, G.J.; Boone, M.J.; Krens, F. A.; Zuidmeer, L.; Van Leeuwen, A.; Akkerdaas, J.; Hoffmann-Sommergruber, K.; Knulst, A.C.; Bosch, D.; Van de Weg, W.E.; Van Ree, R. Silencing the major apple allergen Mal d 1 by using the RNA interference approach. J. Allergy Clin. Immunol., 2005, 115, 364.
81. Gonzalez-Rioja, R.; Ibarrola, I.; Arilla, M.C.; Ferrer, A.; Mir, A.; Andreu, C.; Martinez, A.; Asturias, J.A. Genetically engineered hybrid proteins from Parietaria judaica pollen for allergen-specific immunotherapy. J. Allergy Clin. Immunol., 2007, 120, 602.
82. Nakazawa, T.; Takai, T.; Hatanaka, H.; Mizuuchi, E.; Nagamune, T.; Okumura, K.; Ogawa, H. Multiple-mutation at a potential ligand-binding region decreased allergenicity of a mite allergen Der f 2 without disrupting global structure. FEBS Lett., 2005, 579, 1988.
83. Metz-Favre, C.; Linhart, B.; Focke-Tejkl, M.; Purohit, A.; de Blay, F.; Valenta, R.; Pauli, G. Skin test diagnosis of grass pollen allergy with a recombinant hybrid molecule. J. Allergy Clin. Immunol., 2007, 120, 315.
84. Kussebi, F.; Karamloo, F.; Rhyner, C.; Schmid-Grendelmeier, P.; Salagianni, M.; Mannhart, C.; Akdis, M.; Soldatova, L.; Markovic-Housley, Z.; Von Beust, B.R.; Kundig, T.; Kemeny, D.M.; Blaser, K.; Crameri, R.; Akdis, C.A. A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J. Allergy Clin. Immunol., 2005, 115, 323.
85. Bonura, A.; Corinti, S.; Artale, A.; Di Felice, G.; Amoroso, S.; Melis, M.; Geraci, D.; Colombo, P. A hybrid expressing genetically engineered major allergens of the Parietaria pollen as a tool for specific allergy vaccination. Int. Arch. Allergy Immunol., 2007, 142, 274.
86. van Milligen, F.J.; van 't Hof, W.; van den Berg, M.; Aalberse, R.C. IgE epitopes on the cat (Felis domesticus) major allergen Fel d I: a study with overlapping synthetic peptides. J. Allergy Clin. Immunol., 1994, 93, (1 Pt 1), 34.
87. Immonen, A.K.; Taivainen, A.H.; Narvanen, A.T.; Kinnunen, T.T.; Saarelainen, S.A.; Rytkonen-Nissinen, M.A.; Virtanen, T.I. Use of multiple peptides containing T cell epitopes is a feasible approach for peptide-based immunotherapy in Can f 1 allergy. Immunology, 2007, 120, 38.
88. Saarelainen, S.A.; Kinnunen, T.T.; Buhot, C.; Narvanen, A.T.; Kauppinen, A.K.; Rytkonen-Nissinen, M.A.; Maillere, B.; Virtanen, T.I. Immunotherapeutic potential of the immunodominant T-cell epitope of lipocalin allergen Bos d 2 and its analogues. Immunology, 2008, 123, 358.
89. Kozutsumi, D.; Tsunematsu, M.; Yamaji, T.; Murakami, R.; Yokoyama, M.; Kino, K. Cry-consensus peptide, a novel peptide for immunotherapy of Japanese cedar pollinosis, induces Th1-predominant response in Cry j 1-sensitized B10.S mice. Biol. Pharm. Bull., 2006, 29, 2506.
90. Larche, M. Peptide immunotherapy for allergic diseases. Allergy, 2007, 62, 325.
91. Haselden, B.M.; Kay, A.B.; Larche, M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J. Exp. Med., 1999, 189, 1885.
92. Haselden, B.M.; Larche, M.; Meng, Q.; Shirley, K.; Dworski, R.; Kaplan, A.P.; Bates, C.; Robinson, D.S.; Ying, S.; Kay, A.B. Late asthmatic reactions provoked by intradermal injection of T-cell peptide epitopes are not associated with bronchial mucosal infiltration of eosinophils or T(H)2-type cells or with elevated concentrations of histamine or eicosanoids in bronchoalveolar fluid. J. Allergy Clin. Immunol., 2001, 108, 394.
93. Oldfield, W.L.; Kay, A.B.; Larche, M. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J. Immunol., 2001, 167, 1734.
94. Thomas, W.R.; Hales, B.J.; Smith, W.A. Genetically engineered vaccines. Curr. Allergy Asthma Rep., 2005, 5, 197.
95. Niederberger, V.; Horak, F.; Vrtala, S.; Spitzauer, S.; Krauth, M.T.; Valent, P.; Reisinger, J.; Pelzmann, M.; Hayek, B.; Kronqvist, M.; Gafvelin, G.; Gronlund, H.; Purohit, A.; Suck, R.; Fiebig, H.; Cromwell, O.; Pauli, G.; van Hage-Hamsten, M.; Valenta, R. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc. Natl. Acad. Sci. USA, 2004, 101 Suppl 2, 14677.
96. Gafvelin, G.; Thunberg, S.; Kronqvist, M.; Gronlund, H.; Gronneberg, R.; Troye-Blomberg, M.; Akdis, M.; Fiebig, H.; Purohit, A.; Horak, F.; Reisinger, J.; Niederberger, V.; Akdis, C.A.; Cromwell, O.; Pauli, G.; Valenta, R.; van Hage, M. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int. Arch. Allergy Immunol., 2005, 138, 59.
97. Reisinger, J.; Horak, F.; Pauli, G.; van Hage, M.; Cromwell, O.; Konig, F.; Valenta, R.; Niederberger, V. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J. Allergy Clin. Immunol., 2005, 116, 347.
98. Wohlleben, G.; Erb, K.J. Immune stimulatory strategies for the prevention and treatment of asthma. Curr. Pharm. Des., 2006, 12, 3281.
99. Kline, J.N.; Waldschmidt, T.J.; Businga, T.R.; Lemish, J.E.; Weinstock, J.V.; Thorne, P.S.; Krieg, A.M. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J. Immunol., 1998, 160, 2555.
100. Hirose, I.; Tanaka, H.; Takahashi, G.; Wakahara, K.; Tamari, M.; Sakamoto, T.; Kojima, S.; Inagaki, N.; Nagai, H. Immunomodulatory effects of CpG oligodeoxynucleotides on house dust mite-induced airway inflammation in mice. Int. Arch. Allergy Immunol., 2008, 147, 6.
101. Jahn-Schmid, B.; Wiedermann, U.; Bohle, B.; Repa, A.; Kraft, D.; Ebner, C. Oligodeoxynucleotides containing CpG motifs modulate the allergic TH2 response of BALB/c mice to Bet v 1, the major birch pollen allergen. J. Allergy Clin. Immunol., 1999, 104, 1015.
102. Hochreiter, R.; Stepanoska, T.; Ferreira, F.; Valenta, R.; Vrtala, S.; Thalhamer, J.; Hartl, A. Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen. Eur. J. Immunol., 2003, 33, 1667.
103. Hessel, E.M.; Chu, M.; Lizcano, J.O.; Chang, B.; Herman, N.; Kell, S.A.; Wills-Karp, M.; Coffman, R.L. Immunostimulatory oligonucleotides block allergic airway inflammation by inhibiting Th2 cell activation and IgE-mediated cytokine induction. J. Exp. Med., 2005, 202, 1563.
104. Santeliz, J.V.; Van Nest, G.; Traquina, P.; Larsen, E.; Wills-Karp, M. Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J. Allergy Clin. Immunol., 2002, 109, 455.
105. Pace, E.; Duro, G.; La Grutta, S.; Ferraro, M.; Bruno, A.; Bousquet, J.; Bonsignore, G.; Gjomarkaj, M. Hypoallergenic fragment of Par j 2 increases functional expression of Toll-like receptors in atopic children. Allergy, 2006, 61, 1459.
106. Drachenberg, K.J.; Heinzkill, M.; Urban, E.; Woroniecki, S.R. Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents. Allergol. Immunopathol. (Madr), 2003, 31, 270.
107. Mothes, N.; Heinzkill, M.; Drachenberg, K.J.; Sperr, W.R.; Krauth, M.T.; Majlesi, Y.; Semper, H.; Valent, P.; Niederberger, V.; Kraft, D.; Valenta, R. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin. Exp. Allergy, 2003, 33, 1198.
108. Gauvreau, G.M.; Hessel, E.M.; Boulet, L.P.; Coffman, R.L.; O'Byrne, P.M. Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses. Am. J. Respir. Crit. Care Med., 2006, 174, 15.
109. Saxon, A.; Zhu, D.; Zhang, K.; Allen, L.C.; Kepley, C.L. Genetically engineered negative signaling molecules in the immunomodulation of allergic diseases. Curr. Opin. Allergy Clin. Immunol., 2004, 4, 563.
110. Zhu, D.; Kepley, C.L.; Zhang, M.; Zhang, K.; Saxon, A. A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat. Med., 2002, 8, 518.
111. Zhang, K.; Kepley, C.L.; Terada, T.; Zhu, D.; Perez, H.; Saxon, A. Inhibition of allergen-specific IgE reactivity by a human Ig Fcgamma-Fcepsilon bifunctional fusion protein. J. Allergy Clin. Immunol., 2004, 114, 321.
112. Zhu, D.; Kepley, C.L.; Zhang, K.; Terada, T.; Yamada, T.; Saxon, A. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat. Med., 2005, 11, 446.
113. Terada, T.; Zhang, K.; Belperio, J.; Londhe, V.; Saxon, A. A chimeric human-cat Fcgamma-Fel d1 fusion protein inhibits systemic, pulmonary, and cutaneous allergic reactivity to intratracheal challenge in mice sensitized to Fel d1, the major cat allergen. Clin. Immunol., 2006, 120, 45.